Dietry supplement group for weight loss and cholesterol control OptiBiotix Health booked a first-half loss after modest sales were offset by administrative costs.
Pre-tax losses for the six months through May amounted to £1.26m, compared to losses of £1.19m on-year.
Revenue rose to around £149k, up from around £81k on-year.
'This has been an exciting half year period, with twelve commercial deals signed, six for SlimBiome and six for LP-LDL, making a total of 44 deals since mid-2017,' chief executive Stephen O'Hara said.
'The large number of agreements signed in the last two years demonstrate early commercial progress.'
'The next stage of the process is to ensure these agreements deliver recurring revenue streams to build sales growth in 2019 against a continued low-cost base and create profitable divisions across all areas of the company.'
At 8:01am: (LON:OPTI) Optibiotix Health Plc share price was -5p at 61p